Roche agrees new Kadcyla pricing deal to secure NICE approval

Roche has agreed a new pricing package for its breast cancer drug Kadcyla to secure a recommendation from the National Institute for Health and Care Excellence (NICE).

Final draft guidance from the regulator has been published that recommends Kadcyla be accepted for routine NHS funding, based on the clinical and cost-effectiveness benefits the drug can provide under the new pricing scheme.

Kadcyla is currently being funded through the Cancer Drugs Fund (CDF), which is being restructured by the government, necessitating new supply arrangements for the various therapies provided through the fund.

In addition to Roche's agreement to reduce the cost to the NHS, NICE's decision to recommend the therapy was also informed by an assessment showing the benefits it can offer compared to the current standard of care.

The new agreement means Kadcyla will move out of the CDF into routine NHS funding later this summer, so eligible patients will no longer have to apply for funding for the drug.

Professor Carole Longson, director of the centre for health technology evaluation at NICE, said: "Since we started reassessing the drugs available through the Cancer Drugs Fund, companies have responded positively and shown that they can offer good deals when it comes to pricing."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.